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Redox biological reactions are now accepted to bear the Janus faceted feature of promoting both phy-
siological signaling responses and pathophysiological cues. Endogenous antioxidant molecules partici-
pate in both scenarios. This review focuses on the role of crucial cellular nucleophiles, such as glu-
tathione, and their capacity to interact with oxidants and to establish networks with other critical en-
zymes such as peroxiredoxins. We discuss the importance of the Nrf2-Keap1 pathway as an example of a
transcriptional antioxidant response and we summarize transcriptional routes related to redox activa-
tion. As examples of pathophysiological cellular and tissular settings where antioxidant responses are
major players we highlight endoplasmic reticulum stress and ischemia reperfusion. Topologically con-
ﬁned redox-mediated post-translational modiﬁcations of thiols are considered important molecular
mechanisms mediating many antioxidant responses, whereas redox-sensitive microRNAs have emerged
as key players in the posttranscriptional regulation of redox-mediated gene expression. Understanding
such mechanisms may provide the basis for antioxidant-based therapeutic interventions in redox-related
diseases.
& 2015 Published by Elsevier B.V.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
2. Glutathione and glutathione-related post-translational modiﬁcations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
2.1. GSH-related enzymatic antioxidants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
3. Redox-dependent transcriptional and post-transcriptional regulation of antioxidants: main examples. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
3.1. The Nrf2-Keap1 pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
3.2. NF-κB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
3.3. AP-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
3.4. Role of microRNAs in antioxidant responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
4. Antioxidant responses in speciﬁc pathophysiological contexts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
4.1. ER stress. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
4.2. Ischemia-reperfusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1904.2.1. Post-translational modiﬁcations of mitochondrial proteins in ischemia–reperfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
4.2.2. The Nrf2 pathway in ischemia–reperfusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
4.2.3 Lipid peroxidation products in cardioprotection against ischemia–reperfusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915. Signal transduction in the context of antioxidant responses: some key players . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
5.1. Cytosolic regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915.1.1. Protein tyrosine phosphatases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
5.1.2. Protein Kinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1925.2. Mitochondrial regulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
5.2.1. Targeting mitochondria to eliminate ROS production . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
C. Espinosa-Diez et al. / Redox Biology 6 (2015) 183–1971846. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1931. Introduction
Free radicals and oxidant species may behave as deleterious
and toxic products, involved in cellular and tissular dysfunction.
Overproduction of these species may result in DNA, lipid and
protein damage. Nevertheless, low or moderate concentrations of
reactive oxygen species (ROS) or reactive nitrogen species (RNS)
are also involved in physiological responses as part of signaling
processes and defense mechanisms against infectious agents. In
fact, ROS protect the cell against ROS damage by inducing different
antioxidant responses and re-establishing or maintaining redox
homeostasis. For the sake of clarity in this review we will focus on
endogenous antioxidant systems and the different factors involved
in their regulation.Fig. 1. GSH biosynthetic route and GSH cycle. GSH biosynthesis occurs in two
different and ATP-dependen steps. The ﬁrst and limiting step is carried out by GCL,
formed by two subunits GCLc and GCLm. In this step L-Glu and L-Cys react to form
γ-glutamyl-cisteine. GS is responsible of the second step, that joins L-Gly forming γ-
glutamyl-cisteinyl-glicine (GSH). As well as aerobic respiration or other ROS sources
increase H2O2, that should be metabolized, in this case GPx generating GSSG. This
GSSG could be reduced to GSH again with the help of GR GR, creating a redox cycle,
using as reducing agent NAPDH, from Penthoses Phosphate Pathway (PPP).2. Glutathione and glutathione-related post-translational
modiﬁcations
Antioxidant molecules are in fact nucleophilic and reductant
molecules able to react with oxidants, which are generally elec-
trophiles, giving them one or two electrons. Glutathione (GSH) is
considered the most abundant molecule among endogenous an-
tioxidants. GSH is a reduced peptide consisting of three-residues
(γ-L-glutamyl-L-cysteinyl glycine) which can donate an electron
with the consequence that two electron donating GSH molecules
form oxidized GSSG. In humans, GSH is almost uniquely present in
a quite high concentration (1–10 mM) which allows to scavenge
ROS either directly or indirectly [1]. It can directly react with O2
−•
and some other ROS, but its indirect ROS-scavenging functions,
such as revitalizing other antioxidants, are likely more important;
e.g. it can reduce dehydroascorbic acid which is formed in the
reconversion of α-tocopheroxyl radical to α-tocopherol, a lipophilic
chain breaking antioxidant, which interacts with the poly-
unsaturated acyl groups of lipids, stabilizes membranes and sca-
venges various reactive oxygen species and lipid oxy-radicals [2,3].
As an antioxidant it reacts with ROS, RNS and radicals produced in
association with electron transport, xenobiotic metabolism and
inﬂammatory responses [4,5]. GSH is synthesized from its con-
stituent amino acids forming a tripeptide thiol and this synthesis
requires two ATP-dependent steps (Fig. 1). The ﬁrst and limiting
synthesis is catalyzed by γ-glutamyl-cysteine ligase (GCL) and the
second step mediated by GSH synthetase (GS). GCL is a hetero-
dimeric enzyme composed by a heavy subunit, GCLc (73 kDa) with
catalytic activity and a smaller one, GCLm (33 kDa) that has a
regulatory role on the other subunit [6]. GSH homeostasis in the
cell is not only regulated by its de novo synthesis, but also by other
factors such as utilization, recycling and cellular export. This redox
cycle is known as the GSH cycle and incorporates other important
antioxidant, redox-related enzymes. Aerobic respiration may re-
sult in an increase in hydrogen peroxide, which will be metabo-
lized by glutathione peroxidase (GPx) by converting 2 GSH mole-
cules to its oxidized form (GSSG). GSH is recycled by the action of
glutathione reductase (GR, see below). Moreover, GSH is also able
to react with critical Cys residues in proteins, by forming mixed
disulﬁdes (see below). This is a labile process that can be reverted
by glutathione S-transferase (GST). Another cellular mechanism
used to prevent redox unbalance is exporting GSSG to the extra-
cellular medium. In addition, the biosynthetic capacity to form
GSH is also regulated by allosteric mechanisms and substrateabundance. An excess of GSH in the cell produces a competitive
inhibition in GCLc, while L-Cys is one of the limiting substrates
[6,7].
Alterations in the ratio of the redox pair 2GSH/GSSG towards a
more oxidized status form the biochemical basis of targeting re-
dox-sensitive cysteine residues in proteins by generating mixed
disulﬁdes between the thiol and GSH [2,8]. However, the calcula-
tion and quantiﬁcation of this ratio is not easy and depends on the
detection method, the tissue of interest and the abundance of
recycling enzymes such as GPx1 [9]. This post-translational mod-
iﬁcation, known as S-glutathionylation, is a reversible process,
which has been extensively reviewed elsewhere [10,11]. S-glu-
tathionylation may result in the activation or inactivation of pro-
tein function [12]. Thereby S-glutathionylation is able to modulate
different cellular pathways, and affect gene expression proﬁles by
affecting different transcription factors as Nrf2 (see below), or NF-
κB. Although these mechanisms were initially proposed to be part
of a protective pathway against other irreversible oxidative mod-
iﬁcations [2,8], it was recently shown that S-glutathionylation of
eNOS at Cys689 and Cys908 leads to eNOS uncoupling, diminished
NO production, and enhanced oxidative stress and superoxide
anion production [13]. Thus, S-glutathionylation may be a double-
edged sword in the sense that it may promote antioxidant or pro-
oxidant responses.
Fig. 2. Interconnection of glutaredoxin, peroxiredoxin, thioredoxin, and glu-
tathione containing antioxidant systems. Hydrogen peroxide (H2O2) can be reduced
by peroxiredoxins (Prx) or glutathione peroxidases (GPX), which couple reduction
of H2O2 with oxidation of glutathione (GSH). Oxidized Prx can be reduced by
thioredoxins (Trx). Subsequently, oxidized Trx become reduced by thioredoxin
reductase (TrxR) in a NADPH-dependent manner. Oxidized glutathione disulﬁde
(GSSG) is reduced by glutathione reductase (GR) in the presense of NADPH. Further,
glutaredoxins (Grx) can reduce disulﬁde (S–S) bonds in proteins (Pr), and glu-
tathione S transferase (GST) is using GSH to conjugate and thus to detoxify reactive
electrophilic compounds (R).
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Fig. 3. Two-step mechanism reaction of a peroxiredoxin dimer with hydrogen
peroxide. (i) the sulfhydryl group at the peroxidatic cysteine of one peroxiredoxin
(Prx) subunit is oxidized to sulfenic acid (–SOH); (ii) the sulfenic acid condenses
with the –SH group at the resolving cysteine from the other subunit to form an
intersubunit disulﬁde bond. The disulﬁde bond can be reduced by thioredoxin or
another reductase (red) depending on the species. Continuous peroxide signaling
leads to irreversible hyperoxidation and formation of sulﬁnic acid (–SOOH) at the
peroxidatic cysteine to (shown as the “Hyperoxidation”). The species peroxynitrite
(ONOO–) has been included in the cartoon because it is susceptible of reduction by
peroxiredoxins.
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Glutathione reductase (GR) is the enzyme critical for the re-
duction of GSSG back to GSH. GR utilizes FAD and NADPH to re-
duce one GSSG to two GSH (Fig. 2). The link of GR to oxidative
stress was established due to its role in the ROS-releasing mac-
rophage oxidative burst response as cells lacking GR had a more
persistent response. In addition, GR deﬁciency has been linked to
lupus erythematosus in Afro-Americans, favism and cataracts [14].
Glutathione peroxidases (GPXs; GPX1-8) couple oxidation of GSH
with detoxiﬁcation of H2O2. GPX1 deﬁciency in mice was also
shown to contribute to the development of cataracts at an early
age. From the GPX family members known, GPX1 is the ubiquitous
enzyme that reduces cytosolic, mitochondrial and in some cells
peroxisomal peroxides. GPX2 is an epithelial-speciﬁc form with
highest expression in intestine [15]. GPX3 is a secreted form
mainly expressed in lung and kidney; it is measurable in plasma
and seems to be involved in the protection against external per-
oxides [15]. There are three different isoforms of GPX4 (also
known as phospholipid–hydroperoxide glutathione peroxidase)
derived from a single gene: cytosolic (c-GPX4), mitochondrial (m-
GPX4), and nuclear (n-GPX4) [16]. Unlike other glutathione per-
oxidases, GPX4 has a broad range of substrates; in addition to
H2O2, these include derivatives from cholesterol and cholesteroyl
esters and thymine hydroperoxide [16]. Importantly, the catalytic
sites of various GPX enzymes and thioredoxin reductases (TrxR)
contain selenium in the form of selenocysteine. Selenium is a trace
element, and its appearance in the catalytic centers of antioxidant
enzymes underlines even more its essential biological roles [17]. In
addition to GPX and TrxR, selenoprotein P has also been reported
to have antioxidant properties [17] because selenium-containing
compounds scavenged ROS in vitro and in various animal studies
[18–20].
Glutathione is also a cofactor and substrate for multiple glu-
taredoxins (Grx), which catalyze disulﬁde reductions in the pre-
sence of NADPH and GR [21]. Another important enzyme family
consists of glutathione-S-transferases (GSTs). In humans, 22 family
members known which are classiﬁed in classes based upon their
structure. GSTs are dimeric, with both subunits being from the
same class of GSTs. The activity of GSTs is also dependent upon the
presence of GSH, again stressing its importance as an antioxidantmolecule. The primary role of GSTs is the detoxiﬁcation of reactive
electrophilic compounds, including environmental toxins, and
products of oxidative stress, by conjugation with GSH. Due to the
action of speciﬁc transporters GSH conjugates are removed from
the cell, thereby preventing crucial cellular proteins and nucleic
acids from the action of reactive electrophilic compounds.
A peroxidase activity is not only found in GPX but is also
characteristic of the peroxiredoxin (PRX) family (Fig. 3). Peroxir-
edoxins are thiol-speciﬁc proteins that react with H2O2 at a very
high rate [22]. The activity of peroxiredoxins is crucially depen-
dent on a conserved, so called ’peroxidatic’, cysteine residue in the
active site. Importantly, the catalytic cysteine can become hyper-
oxidized and catalytically inactive but still be able to participate in
ROS signaling. Hyperoxidized peroxiredoxin can be recycled by
sulphiredoxin [23–25]. It is important to note that PRXs can also
reduce and detoxify peroxynitrite and a wide range of organic
hydroperoxides. Prx1, 2 and 4 are found primarily in the cytoplasm
but are also expressed in nuclei. In addition, Prx1 is also present in
mitochondria and peroxisomes while Prx4 is found in lysosomes
[26,27]. While Prx3 is localized in the mitochondria [26], Prx5 is
found in mitochondria, cytoplasm, nuclei and peroxisomes [28]. It
has been suggested that Prx2, due to its high reaction rate and
abundance, traps almost all H2O2 in vivo [29–31]. Oxidized cy-
steine residues of Prx are speciﬁcally reduced by thioredoxins
(Trx), thiol-disulﬁde oxidoreductases that can be oxidized upon
oxidative stress caused by a variety of stimuli [32]. Oxidized Trx (as
well as other oxidized cellular proteins) can be reversibly reduced
by thioredoxin reductase (TrxR) in a NADPH-dependent manner
[32]. Interestingly, a compartment-speciﬁc specialization can also
be found here: Trx1 and TrxR1 are in the cytoplasm and nucleus
whereas Trx2 and TrxR2 show mitochondrial localization. Overall,
they appear to have a protective function against oxidative stress
[26,33]; e.g. the Trx/TrxR system supports the activity of ribonu-
cleotide reductase and inhibits apoptosis signal-regulated kinase-1
[33].
Among the antioxidant enzymes SODs catalyze the dismutation
of O2
−• to H2O2, and catalase stops formation of OH by converting
H2O2 to oxygen and water [34]. Whereas catalase is considered to
be a rather peroxisome-speciﬁc antioxidant enzyme and will not
be covered in this review, SODs are topologically conﬁned. The Cu-
and Zn-containing Cu/ZnSOD (SOD1) is located mainly in the
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(SOD2) is found in the mitochondrial matrix. A third extracellular
variant, EcSOD or SOD3, is secreted and forms a glycosylated
heterotetramer bound to the extracellular matrix [35] but again
the enzyme activity is Cu-, Zn-dependent. Importantly, changes in
the cytosolic Cu/ZnSOD (SOD1), mitochondrial MnSOD (SOD2) or
extracellular EcSOD (SOD3) activity or expression correlate with
ROS levels [36].
Dysfunction or failure in the dismutation process is linked to
the pathogenesis of a number of diseases [36]. Thereby the impact
and tissue affected by the different SODs seems to vary; SOD1 has
been clearly linked to amyotrophic lateral sclerosis, the extra-
cellular superoxide dismutase (SOD3, ecSOD) seems to be involved
in hypertension, acute respiratory distress syndrome, or chronic
obstructive pulmonary disease [37] and SOD2 has been linked
with carcinogenesis [36]. The removal of superoxide anion by
superoxide dismutase(s) appears to be important for a number of
cellular processes, among them mitochondrial and ER function
(see below).3. Redox-dependent transcriptional and post-transcriptional
regulation of antioxidants: main examples
Multiple H2O2 sensors and pathways are triggered converging
in the regulation of transcription factors, including AP-1, Nrf2,
CREB, HSF1, HIF-1, TP53, NF-κB, Notch, SP1 and CREB-1, which
induce the expression of a number of genes, including those re-
quired for the detoxiﬁcation of oxidizing molecules and for the
repair and maintenance of cellular homeostasis, controlling mul-
tiple cellular functions like cell proliferation, differentiation andFig. 4. Keap1 dependent regulation of Nrf2. Under basal conditions, Nrf2 is sequestere
proteasomal degradation of Nrf2. Inducers react with speciﬁc cysteine residues in Keap1,
Nrf2 heterodimerizes with small Maf proteins and binds to the antioxidant response elapoptosis. In addition, the family of FoxO-related transcription
factors plays an important role in redox responses and is the ob-
ject of a separate review within this thematic series. H2O2-medi-
ated regulation of transcription factors can take place at different
levels: synthesis/degradation, cytoplasm-nuclear trafﬁcking, DNA
binding and transactivation [31]. In this section we focus on the
most important transcription-related pathways involved in anti-
oxidant responses.
3.1. The Nrf2-Keap1 pathway
The Nrf2 (nuclear factor erythroid 2 [NF-E2]-related factor 2)-
Keap1 (Kelch-like ECH-associated protein 1) pathway is the major
regulator of cytoprotective responses to oxidative and electrophilic
stress [38,39]. Nrf2 is a basic region-leucine zipper-type tran-
scription factor that belongs to the Cap ‘n’ Collar (CNC) family of
regulatory proteins that also includes NF-E2, Nrf1, Nrf3, Bach1 and
Bach2 [40]. The protein contains seven functional domains, known
as Neh1–Neh7. The major regulatory domain is Neh2, which is
located in the N terminus of Nrf2. The Neh2 domain contains se-
ven lysine residues critically involved in ubiquitin conjugation [41]
as well as two binding sites, known as ETGE and DLG motifs, that
help to regulate Nrf2 stability [42,43].
The Nrf2 protein is rapidly turned over; it has a short half-life
under basal conditions (7–15 min) which is increased to 30–
100 min in the presence of inducers [44,45]. The Nrf2 protein
stability is primarily regulated by Keap1 [46] (Fig. 4). The ETGE and
DLG motifs within Nrf2 interact with Keap1. Keap1 is a substrate
adaptor protein for a Cullin 3 (Cul3)-dependent E3 ubiquitin ligase
complex; hence binding of Keap1 with Nrf2 mediates ubiquitina-
tion and subsequent proteasomal degradation of Nrf2 [41,46–50].d in the cytosol by a Keap1 homodimer, which facilitates the ubiquitination and
leading to the release of Nrf2 and allowing its nuclear translocation. In the nucleus,
ement (ARE), activating the expression of a battery of cytoprotective genes.
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and oxidants [51]. In the presence of reactive oxygen species, cri-
tical cysteine residues in Keap1 become oxidized leading to a
conformational change of Keap1, which prevents its binding to
Nrf2. As a consequence, Nrf2 ubiquitination and degradation is
stopped, and its nuclear translocation promoted.
Among the 27 cysteine residues within Keap1, Cys151 seems to
be the most critical sensor residue which mediates the formation
of an intermolecular disulﬁde – Cys151–Cys151 – between two
Keap1 molecules. Thus, in response to a diverse array of stimuli,
redox-sensitive residues, especially Cys151 within Keap1, can be
covalently modiﬁed, allowing Nrf2 to evade Keap1-mediated ubi-
quitination [52,53]. As a result, Nrf2 accumulates in the nucleus
and heterodimerizes with a small Maf protein. The Nrf2-small Maf
heterodimer binds to regulatory gene regions known as ARE sites
with a consensus sequence 5′-TGACnnnGC-3′, also called electro-
phile response elements (EpRE) [54]. Substances able to induce a
response at the ARE are derived from a variety of sources, in-
cluding phytochemicals and derivatives such as genistein, quer-
cetin, curcumin and sulforaphane; therapeutics such as oltipraz,
auranoﬁn and acetaminophen; environmental agents like para-
quat and metals and endogenous inducers such as nitric oxide,
nitro-fatty acids, hydrogen peroxide and 4-hydroxynonenal [55].
Nrf2 target genes mainly include enzymes involved in the anti-
oxidant response such as NAD(P)H:quinone oxidoreductase 1
(NQO1), glutathione S-transferases (GSTs), cysteine–glutamate
exchange transporter, and multidrug resistance-associated
protein.
In addition to cysteine-thiol modiﬁcation, several other me-
chanisms have been described to regulate Nrf2 signaling. For ex-
ample, some proteins, such as autophagy substrate p62 and p53-
regulated p21, interfere with the Keap1-dependent ubiquitination
of Nrf2 by disrupting Nrf2-Keap1 binding causing persistent acti-
vation of Nrf2 [56,57]. ROS also regulate Nrf2 by promoting the
Ser209 phosphorylation of eIF4E, the initiation factor 4F complex
which recruits the 40S ribosome to the 5′-UTR of the Nrf2 mRNA.
An additional level of regulation is provided by an Internal Ribo-
some Entry Site (IRES) sequence in the 5′-UTR in the Nrf2 mRNA.
IRES activity is regulated by IRES trans-acting factors (ITAFs),
which recruit eIFs and ribosomes to initiate translation. One of
such ITAFs, La Autoantigen, is activated by ROS promoting de-
phosphorylation of Ser366 or phosphorylation of Thr301 by AKT.
Concerning Nrf2 export from the nucleus, oxidation of Cys183 in
Nrf2 inhibits its binding to the nuclear exporting protein CRM1,
while the phosphorylation of Tyr568 by FYN, a kinase activated by
GSK-3β strengthens this interaction [58].
Moreover, Nrf2 can bind to the E3 ubiquitin ligase β-TrCP (β-
transducing repeat-containing protein) via its Neh6 domain,
which can be phosphorylated by GSK-3β (glycogen synthase ki-
nase 3β), leading to Cullin 1 (Cul1)-dependent ubiquitination and
degradation of Nrf2 in a Keap1-independent manner [44,58]. GSK-
3β is inhibited by phosphorylation, which can be catalyzed by AKT,
ERK, p38 MAPK and PKC kinases, all known to be activated by
H2O2. Also, Nrf2 cross-interacts with several other signaling
pathways such as NF-κB, AhR, p53, and homeodomain transcrip-
tion factors, which also expands the scope of Nrf2-regulated genes
[59–62]. Additionally, Nrf2 phosphorylation by protein kinase RNA
(PKR)-like ER kinase (PERK) or PKC-δ, both activated by ROS,
causes dissociation of the Nrf2/Keap1 complex.
Post-translational modiﬁcations at the level of Keap1 that
prevent its interaction with Nrf2 are another mechanism leading
to Nrf2 activation. Indeed, Keap1 phosphorylation at Tyr141 ren-
ders the protein highly stable and its dephosphorylation induced
by hydrogen peroxide results in rapid Keap1 degradation and Nrf2
activation [63]. Interestingly, Keap1 knockout mice die short after
birth, but the lethal phenotype can be reversed by the doubleknockout of Keap1 and Nrf2 [64], which suggests that either ex-
cessive or insufﬁcient Nrf2 activity may be detrimental for normal
physiology. In fact, the constitutive activation of the Nrf2 pathway
can be beneﬁcial for tumor survival [65].
3.2. NF-κB
The NF-κB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells)/REL family of transcription factors consist of homo-
and heterodimers of ﬁve distinct proteins, the REL subfamily
proteins (p65/RELA, RELB, and c-REL) and the NF-κB subfamily
proteins (p50, and p52, and its precursors p105 and p100, re-
spectively). All NF-κB/REL proteins contain a Ref-1-homology do-
main (RHD), which is responsible for dimerization, recognition
and binding to DNA as well as interaction with the inhibitory κB
(IκB) proteins. The IκB family is composed of IκB-α, IκB-β, IκB-ϵ,
IκB-γ, and BCL-3, all of which possess typical ankyrin repeats that
bind to the RHD of NF-κB/REL proteins to interfere with their
function. The IκB-kinase complex (IKK complex) catalyzes phos-
phorylation of IκBs with the result that IκBs are targeted for de-
gradation by the 26S proteasome thereby freeing NF-κB. The latter
then binds to the DNA consensus sequence 5′-GGGRNNYYCC-3′ (R
is a purine, Y is a pyrimidine, and N is any base) in the promoter/
enhancer regions of target genes [66].
Activation of IKK occurs also by phosphorylation and is cata-
lyzed by an IKK kinase, including TGF-β-activated kinase (TAK1),
AKT, or NF-κB inducing kinase-1 (NIK1), all of which can be
regulated by H2O2 [67]. Alternatively, the reduced form of the
dynein light chain protein LC8 binds to IκB and inhibits its phos-
phorylation by IKKs. H2O2 induces dimerization of LC8 by a dis-
ulﬁde bond, promoting dissociation from IκB, and NF-κB activation
[68]. On the other hand, inhibition of activation of NF-κB by H2O2
can be mediated by Keap1-dependent degradation of IKKβ [69].
NF-κB target genes mainly include enzymes involved in the
antioxidant response such as ferritin heavy chain [70] and SOD2
[71]. Another NF-κB target gene that contributes to both survival
and innate immune functions is the HIF-1α gene, encoding the
oxygen-regulated subunit of the hypoxia responsive transcription
factor HIF-1 [72]. On the other hand, hydroquinone and tert-butyl
hydroquinone, prototypes of phenolic antioxidants, block lipopo-
lysaccharide (LPS)-induced transcription of TNFα and NF-κB as
they block the formation of NF-κB/DNA binding complexes [73].
3.3. AP-1
AP-1 (activator protein 1) is a family of dimeric bZIP tran-
scription factors including Jun, Fos, ATF/CREB, JDP and MAF that
usually form heterodimers that bind to a TPA-responsive element
(TRE, 5′-TGAG/CTCA-3′) or cAMP response elements (CRE, 5′-
TGACGTCA-3′). They regulate several cellular processes, including
cell proliferation, apoptosis, survival, and differentiation. AP-1,
when upregulated, concentrates in the nucleus to activate gene
expression [74]. H2O2 was shown to induce transcription of both
c-JUN and c-FOS via activating the JNK, p38 MAPK and ERK sig-
naling cascades [75], while antioxidants like butylated hydro-
xyanisole (BHA) and pyrrolidine dithiocarbamate (PDTC) induce
AP-1 binding activity and AP-1-dependent gene expression in-
cluding glutathione S-transferase [76].
Although several other pathways can be regulated by ROS (see
above), the primary responses against different intensities of in-
termediate oxidative stress are mainly modulated by the co-
operation of the three pathways: Nf-κB, AP1 and MAP kinases.
However, with increasing oxidative stress, the Nrf2/ Keap pathway
(see above) is also needed to induce antioxidant defenses and to
minimize oxidative damage. When these defenses are not strong
enough to contend against oxidative stress, the cell induces
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pore, as an efﬁcient way to decrease ROS production, by decreas-
ing the mitochondrial membrane mitochondrial potential. How-
ever, this increases the oxidative state in the cell [77,78], resulting
in a homeostatic disruption of the redox balance, cell damage, and
apoptosis [79].
3.4. Role of microRNAs in antioxidant responses
MicroRNAs are endogenous non-coding RNAs. They are small
single-stranded RNAs (22–26 nt) and are now considered essential
post-transcriptional regulators of gene expression. They bind to
the 3′-UTR region of mRNAs by Watson-Crick complementarity
and through different molecular interactions, they are able to
block their translation into proteins. In 1998, Craig Mello and
Andrew Fire showed how the formation of double stranded RNA in
C. elegans produced transcriptional silencing and they described
the ﬁrst microRNA named Lin-4 in this same model [80,81]. Dur-
ing the last decades knowledge in this ﬁeld has grown ex-
ponentially in such a way that a recent update of the main miRNA
database (miRbase 21, June 2014) [82], listed 28,645 miRNAs in
more than 142 species. The vast majority of these microRNA are
highly conserved across species, including non-vertebrate ones as
Drosophila or C. elegans.
MicroRNA transcription depends on its localization across the
genome. These small RNAs can be encoded by intronic regions
(about 80%) [83], intergenic regions, non-coding genes or even
exons [84]. Transcriptional regulation of microRNAs is a complex
process and has been reviewed in depth elsewhere [85,86]. miR-
NAs are also processed sequentially in the nucleus and cytoplasm
by speciﬁc proteins ﬁnally leading to the generation of a mature
miRNA (for review see [85,87]).
In the last years miRNAs have been found to regulate stress
responses including redox balance, to the extent that the term
“redoximiRs” has been coined to deﬁne a subset of miRNAs that
either regulate redox pathways or are themselves regulated by the
redox status [88]. As an example, a signiﬁcant number ofTable 1
.
microRNA ID Target Relevance/disease Reference
RedoximiRs
miR-144 Nrf2 Sickle cell disease [94]
miR-28 Nrf2 Breast cancer [95]
miR-27b Nrf2 Liver ﬁbrosis [96]
miR-34a Nrf2 Liver aging [97–99]
miR-132 Nrf2 Nephrotoxicity [89]
miR-200a Keap1 Breast cancer/ﬁbrosis [92,100]
miR-155 Bach1 Cardiovascular diseases,
carcinomas
[101–103]
MitomiRs
miR-27 MFF Mitochondrial ﬁssion [113]
miR-34a Txnrd2 Renal senescence [114]
miR-145 Bnip3 [115]
miR181a Bcl-2 Heart disease [116]
miR-210 ISCU/ AIFM3 Hypoxia/cancer [117]
miR-335 SOD2 Renal senescence [114]
miR-494 Foxj3/ mtF2 Skeletal muscle differentiation [118]
HipoxymiRs
miR-155 HK2 Hypertension [122]
miR-210 GPD1L/ISCU/
COX10
[123]
miR-200 PHD2 Ischemia/precondition [124]
miR-1/133 Hsp60/ Hsp70/
IGF-1/ Bcl-2
Ischemia/precondition [124]
miR-34a Sirt1 Cardiovascular disease/myo-
cardial infartation
[125]publications describe miRNAs that might target the Nrf2 pathway
or that of its co-regulators Keap1 and Bach1 (Table 1) [88–103].
Also, we have recently described one miRNA, miR-433, which
targets GSH biosynthetic enzymes in an Nrf2-independent man-
ner, resulting in decreased GSH levels and antioxidant capacity
with important implications for organ ﬁbrosis [104]. Of interest
Yang et al. have described Nrf2 and GSH regulation in hepatic ﬁ-
brosis produced by miR-27b, a microRNA modulated by c-Myc
[96].
In the case of Dicer, one of the endonucleases involved in
miRNA maturation, several publications have reported its down-
regulation in aging, senescence and stress models, hence altering
the abundance of mature miRNA number [105,106]. Dicer down-
regulation can be prevented by the use of exogenous molecules
with antioxidant potential, such as resveratrol and sulforaphane,
both known to enhance Nrf2 activation. This is consistent with the
fact that Dicer bears ARE sequences in its promoter region, which
are conserved in human and murine species [105]. The NF-κB fa-
mily of transcription factors (see above) is also able to regulate
acute stress responses during inﬂammation through their inter-
action with miRNAs, speciﬁcally by upregulating the expression of
miR-9, miR-155 and miR-146. Interestingly, some of the validated
target genes for these three miRNAs are also pro-inﬂammatory
molecules themselves [107]. Thus, these miRNAs may contribute
to limit the duration of acute stress responses and reduce their
related damage [108].
MicroRNAs are also susceptible of suffering epigenetic mod-
iﬁcations that modulate their expression. Reciprocally, epigenetic
enzymes like histone deacetylases (HDAC) and DNA-methyl
transferases are also targets of oxidative stress and hence changes
in their activities may result in changes in miRNA expression
[109,110].
The study of miRNAs in pathological contexts has been useful
to link them with new targets including enzymes professionally
dedicated to ROS generation such as NOXs. For example, NOX4 has
been reported to be regulated by miR-25, miR-146a and miR-23a
[111]. Moreover other miRNAs, as miR-210 and miR-128a, have
been identiﬁed in mitochondria as capable of regulating their
metabolic activity [112]. These mitomiRs may play a role in the
initiation and progression of cardiovascular disease (Table 1) [113–
118]. Regarding other stress conditions, the unfolded protein re-
sponse or endoplasmic reticulum (ER) stress (see below) includes
an adaptive response whereby some miRNAs are modulated or
regulate ER signaling. For example ER stress induces changes in
the localization of AGO proteins, one of the essential set of proteins
in the RISC complex, suggesting a miRNA repression role during ER
stress [119]. However, other miRNAs are upregulated in these
conditions [120]. In addition, other environmental stresses such as
hypoxia also induce a speciﬁc subset of miRNAs (hypoximiRs),
some of them involved in antioxidant responses [121–125].
Among these, miR-155, miR-210, miR-200 or miR-24 are related to
the archetypal hypoxia-regulated transcription factor Hif-1α. In
the context of ischemia–reperfusion (see below) miR-1 and miR-
133 have been described in the heart in the setting of arrytmhia
[124,126] while the miR-34a/Sirt1 pathway has been reported to
be protective [127] ( Table 1).4. Antioxidant responses in speciﬁc pathophysiological
contexts
Obviously, antioxidant responses are involved in an enormous
amount of cellular and tissular processes in relation to both phy-
siology and pathosphysiology. Excellent reviews covering these
issues are already available [8,128–130]. For the sake of clarity we
now discuss in depth two examples, one related to a cellular
Fig. 5. Protein folding in the endoplasmic reticulum is coupled to ROS formation.
The ER enzymes PDI and ERO1 are crucial for protein folding. PDI oxidizes thiol (SH)
groups, i.e. generates disulﬁde bonds, in the folding substrates, thereby it accepts
electrons (e) and becomes reduced. Ero1 re-oxidizes PDI by using its FAD moiety
to transfer electrons from PDI to molecular oxygen (O2) to form hydrogen peroxide
(H2O2), which may give rise to further formation of ROS. Hydrogen peroxide may
also be used by peroxiredoxin 4 (Prx4) to oxidize PDI, thereby increasing the efﬁ-
ciency of Ero1-dependent disulﬁde bond formation.
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a relevant pathophysiological common event, ischemia–
reperfusion.
4.1. ER stress
The endoplasmic reticulum (ER) has two principal major
functions. First, it is the primary site of protein synthesis and
packaging, second, it plays a central role in metabolism and var-
ious signaling processes. The synthesis and the packing of proteins
within the ER is strongly coupled to native disulﬁde bond forma-
tion. Correct disulﬁde bond formation is coupled to oxidation,
reduction and isomerisation of disulﬁde bonds within the re-
spective proteins. Indeed, there is growing evidence that a large
number of different gene families and redox carriers play a role in
the supply of redox equivalents to achieve a correct protein dis-
ulﬁde bond formation.
The rate-limiting step for disulﬁde bond formation is late-stage
isomerization, which is necessary to achieve a substantial regular
secondary protein structure. Since protein folding is not error-free,
correction of incorrect disulﬁde bonds requires a partial unfolding
of the already formed structures. Remarkably, proper folding and
disulﬁde bond formation of proteins appears to be dependent on
the redox status within the ER. Although reducing conditions
prevail in the cytosol, the lumen of the ER represents a more
oxidizing environment, with a higher ratio of oxidized to reduced
glutathione [GSSG/GSH] [131]. Especially, reduced glutathione
(GSH) or protein thiols react with ROS and thus contribute to
cellular redox homeostasis. In particular, GSH is considered as the
major thiol-disulﬁde redox buffer of cells and often the ratio be-
tween GSSG and GSH is used to determine the redox state. In the
cytoplasm, the ratio of reduced glutathione to oxidized glu-
tathione is 450:1 [132]. By contrast, this ratio is 1:1 to 3:1 in the
ER. It appears that the oxidizing conditions are mainly important
for de-novo disulﬁde bond formation of most proteins synthesized
in the ER. However, disulﬁdes can also be reduced in the ER, and
hence redox homeostasis must be maintained.
In general the factors catalyzing disulﬁde bond formation be-
come reduced and in order to fulﬁll further catalytic cycles these
factors need to be re-oxidized [133]. In eukaryotic cells, in parti-
cular mammalian cells, it is believed that molecular oxygen
functions as the ﬁnal electron acceptor. Within that system, the ER
resident oxidoreductase Ero1 and protein disulﬁde isomerase
(PDI) appear to play key roles [134,135]. Overall, this implies that
disturbances in the nutrient and metabolic ﬂux are important ef-
fectors of Ero1 and PDI function and could thereby contribute to
the generation of ROS and the build-up of an ER stress response.
The ER stress or unfolded protein response (UPR) is in general
triggered when the ER function is diminished, e.g. when the entry
of newly synthesized proteins exceeds the folding capacity. The
accumulation of unfolded proteins within the ER leads to an ac-
tivation of signaling events with the aim to increase the folding
capacity and to reduce folding load. The folding capacity is en-
hanced after ER enlargement [136] and synthesis of ER resident
molecular chaperones and foldases [137]. Decreasing expression of
genes encoding secretory proteins [138] as well as increasing the
ER-associated degradation (ERAD) of slowly folding or misfolded
proteins [139] reduces the folding load. Three distinct branches of
the ER stress response are in principle distinguished; the double-
stranded RNA-activated protein kinase (PKR)-like endoplasmic
reticulum kinase (PERK) branch, the inositol requiring kinase 1
(IRE1) branch, and the activating transcription factor 6 (ATF6)
branch. All three components associate with the ER luminal cha-
peron BiP (also known as glucose-regulated protein 78, GRP78; or
Kar2p in yeast). Once unfolded proteins accumulate in the ER, BiP
preferentially associates with the unfolded proteins instead ofPERK, ATF6, and IRE1, resulting in activation of their downstream
signalling molecules [133]. So far, the cross-talk between ROS and
ER stress appears to be most effective for the PERK branch. Acti-
vation of PERK promotes phosphorylation of the α-subunit of eu-
karyotic translation initiation factor 2 (eIF2α) [140] with the result
of a block in protein translation-initiation except that of ATF4.
ATF4 in turn induces expression of genes like growth arrest and
DNA damage-34 (GADD34), and CAAT/Enhancer binding protein
(C/EBP) homologous protein (CHOP) [141]. In addition, another
direct PERK target appears to be Nrf2 (see above). Interestingly,
Nrf2-/- cells are very sensitive to ER stress [142] implying that ER
stress via PERK phosphorylates Nrf2, resulting in its dissociation
from Keap1, nuclear localization of Nrf2, which, after hetero-
dimerically partnering with other transcription factors, activates
transcription through ARE binding as detailed above.
Although a redox unbalance can be caused by affecting the
PERK branch, most ROS in the ER appear to be generated via Ero1
[143,144]. In humans, there are two ERO1 isoforms, hERO1-La and
hERO1-Lb [145–147], which contain ﬂavin adenine dinucleotide
(FAD). Indeed, overexpression of both Ero1 proteins shifts the re-
dox state of PDI towards the oxidized form (Fig. 5), which thus also
inﬂuences oxidation of PDI substrates [148,149]. The isoform Ero1α
was also localized in the mitochondria-associated membrane
(MAM), and this localization depends on the oxidizing conditions
within the ER [150]. During disulﬁde bond formation electrons
pass several thiol-disulﬁde exchange reactions, the thiols of the
substrate, PDI and Ero1 from where they ﬁnally reach molecular
oxygen [143]. In a simplistic view, Ero1 usually donates a disulﬁde
bond to PDI and at the same time the receiving electrons are
passed on via Ero1´s FAD moiety to reduce oxygen and to generate
hydrogen peroxide (Fig. 5) [151,152]. Interestingly, the hydrogen
peroxide produced can be used by the ER-localized peroxiredoxin
4 to oxidize PDI and some PDI family members. This process does
not only increase the efﬁciency of the Ero1-driven disulﬁde bond
formation but also allows disulﬁde bond formation via alternative
sources of H2O2 [153,154]. Although these ﬁndings underline the
importance of hydrogen peroxide for proper disulﬁde bond for-
mation, the incomplete reduction of oxygen during this process
results in the formation of superoxide anion radicals, which can
then be dismutated to H2O2 or converted to other ROS.
In addition, removal of superoxide by SODs appears to be im-
portant for ER function. This is supported by ﬁndings from mice
transgenic for a non-functional Cu/Zn-superoxide dismutase mu-
tant. These mice show protein aggregate formation and extensive
dilation of the ER along with degeneration of motor neurons of the
spinal cord, features also seen in patients with amyotrophic lateral
sclerosis [155–157]. Whether the ER dilation observed in these
Fig. 6. S-Nitrosylation of ND3 Cys39 protects from IR injury. The low activity of complex I after ischemia causes the ND3 Cys39 to become exposed. Reperfusion of ischemic
tissue rapidly reactivates complex I and generates superoxide leading to oxidative damage and cell death. The presence of MitoSNO or other S-nitrosylating agents at
reperfusion, causes the exposed ND3 cysteine to become S-nitrosylated, holding complex I in a low activity state and decreasing ROS production. Complex I is gradually
reactivated through the reduction of the S-nitrosothiol by glutathione and thioredoxin.
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indirect result via activation of signalling events is not known yet.
However, the Cu/Zn-superoxide dismutase-induced degeneration
of neurons could be blocked by overexpression of the cytosolic
chaperone heat-shock-protein 70 (HSP70) [158,159] suggesting
that cytosolic ROS may affect protein folding in the ER. This is
further supported by the ﬁnding that mutant CuZn-superoxide
dismutase induces BiP (GRP78) levels [156].
The connection between oxygen, ROS, energy metabolism and
ER resident proteins is also underlined by the fact that some of the
latter, known as glucose-regulated proteins (GRPs) [160], are in-
duced by hypoxia [155,161,162]. In line with this, severe hypoxia
or anoxia can also activate ATF4 [163,164]. Although ER stress and
anoxia induce ATF4, the latter was shown to be independent of
hypoxia-inducible transcription factors (HIFs). However, the link
between ER function and regulation of the O2-sensitive HIF-1α
subunit seems to be independent of ATF4 since HIF-1α localizes to
the perinuclear ER membrane under normoxia, where ROS such as
hydroxyl radicals are generated in an iron-dependent Fenton re-
action [165]. Moreover, the so called transmembrane proline
4 hydroxylase (P4HTM), one member of the four HIF-proline hy-
droxylases, which are critically involved in the regulation of HIF
protein stability was found to be an ER resident enzyme [166].
Interestingly, from the two mammalian Ero members only
Ero1Lα but not Ero1Lβ appears to be under transcriptional control
from HIF-1 [167]. Thus, ROS-dependent HIF-1α regulation may be
part of a feedback cycle contributing to thiol-oxidation in the ER
via adaptation of Ero1Lα transcription to the overall cellular redox
status.
However, ER-derived ROS, e.g. due to the action of Ero1, maynot only have an intricate role in disulﬁde bond formation but also
for the regulation of cell death and life span. This is in line with
data showing that ER stress induces accumulation of ROS in PERK
or ATF-4 knockout cells to higher levels than in wild-type cells
[144] and that this contributes to apoptosis and a reduced life span
in C. elegans. Interestingly, repression of Ero-1 restored normal life
span in C. elegans with repressed PERK expression [144]. Further-
more, the cytokine TNFα caused cell death in a ROS- and ER stress
dependent fashion in murine ﬁbrosarcoma L929 cells [168].
However, pre-conditioning these cells with the ER stressor tuni-
camycin substantially inhibited TNFα-induced ROS accumulation
and cell death. Within that scenario, the tumor necrosis factor
receptor-associated factor 2 (TRAF2) was found to interact with
the cytosolic domain of IREα [169] and with apoptosis signal-
regulating kinase 1 (ASK1) [170,171]. This trimeric complex can be
activated by ROS involving thioredoxin, another interacting part-
ner of ASK1 [172–174]. Oxidative stress disrupts the ASK1–thior-
edoxin complex by oxidation of thioredoxin and thereby activating
ASK1 [173] and subsequently JNK, p38 and cell death [175]. In-
terestingly, the Jun activation domain-binding protein (JAB-1, also
known as COP9 signalosome subunit 5) may be a negative feed-
back regulator since it was shown that it interacts with IRE1α
[176]. Thus, ER stress and oxidative stress may induce cell death by
using the same molecular complex consisting of IREα/TRAF2/ASK1/
thioredoxin with JAB1 acting as negative regulator.
4.2. Ischemia-reperfusion
The process of ischemia followed by reperfusion is often ac-
companied by the activation of an injurious cascade. Although the
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derstood, there is considerable evidence implicating ROS as an
initial cause of the injury. Ischemia results in a build-up of NADH
that, upon reperfusion, generates a burst of free radicals from the
electron transport chain (ETC). This can adversely alter proteins
and DNA, and further propagate lipid radical reactions that pro-
duce electrophile species.
4.2.1. Post-translational modiﬁcations of mitochondrial proteins in
ischemia–reperfusion
The speciﬁc modiﬁcations of mitochondrial proteins leading to
improved mitochondrial function have the potential to modulate
cardiac IR damage. The metabolism of (NO) can lead to the S-ni-
trosylation of proteins containing thiol groups, including mi-
tochondrial proteins, thereby reversibly regulating their activity. In
particular, complex I, the entry point for electrons from NADH into
the respiratory chain, can be S-nitrosylated [177–179], which may
alter its activity and thereby protect against damage during IR
injury [180,181]. In agreement with this, mitochondria-targeted
S-nitrosothiols (MitoSNO), which induce functional modiﬁcation
of mitochondrial proteins following S-nitrosylation, protect
against heart IR injury [182–184]. This modiﬁcation of complex I
appears to increase superoxide production from the complex
[178,185]. However, in the context of IR, reversible S-nitrosylation
of complex I, in particular, a speciﬁc Cys residue (Cys 39) within
ND3 (Fig. 6), slows the reactivation of mitochondria during the
ﬁrst minutes of reperfusion, thereby decreasing ROS production,
oxidative damage and tissue necrosis [184]. In addition, consistent
with their potential role in cardioprotection, S-nitrosothiols were
detected in mitochondria isolated from perfused rat hearts sub-
jected to ischemic preconditioning [177,186].
Besides S-nitrosylation, deacetylation of mitochondrial proteins
has been reported to attenuate IR damage. The sirtuin family are
NADþ-dependent protein deacetylases that mediate the effects of
caloric restriction [187]. It has been shown that caloric restriction
primes cardiac mitochondria for ischemic stress by deacetylating
speciﬁc mitochondrial proteins of the ETC [188], suggesting that
deacetylation of speciﬁc mitochondrial proteins by sirtuin pre-
serves mitochondrial function and attenuates myocardial damage
during IR.
4.2.2. The Nrf2 pathway in ischemia–reperfusion
Since the generation of reactive species has been involved in
the pathogenesis of IR, reducing oxidative stress is a potential
therapeutic approach to prevent IR injury. Nrf2 accumulates in the
nucleus after IR in cardiac [189] and renal tissues [190]. Moreover,
several compounds that activate the Nrf2 pathway are protective
against IR damage. Thus, curcumin, a natural compound in tur-
meric with antioxidant activity via the Nrf2 pathway, protects
neurons from death caused by oxygen and glucose deprivation in
an in vitro model of IR [191], and exerts beneﬁcial effects against
cardiac [192] and renal [193] IR injury. Likewise, mono-carbonyl
analogues of curcumin such as 14p have been reported to decrease
oxidative stress and limit myocardial IR injury via Nrf2 activation
[194]. In addition, sulforaphane, a compound obtained from cru-
ciferous vegetables, which induces Nrf2-dependent gene expres-
sion, attenuates liver injury induced by intestinal IR in rats [195],
protects neurons and astrocytes from delayed cell death induced
by oxygen and glucose deprivation [196,197], reduces the infarct
size of isolated perfused rat hearts subjected to IR [198], and
prevents renal injury caused by IR in vivo and in vitro [199]. This
compound also protects rat hearts from early injury after experi-
mental transplantation [200]. Taken together, these observations
indicate that the activation of the Nrf2 pathway protects against
IR injury and is a potential target to ameliorate this type of
damage.4.2.3 Lipid peroxidation products in cardioprotection against ische-
mia–reperfusion
As a result of oxidative damage, lipid peroxidation products
accumulate in the heart. Mitochondria are both a primary source
and target of lipid peroxidation products [201]. Reactive aldehydes
such as 4-hydroxy-2-nonenal (4-HNE) are formed during cardiac
IR. High concentrations of aldehydes are responsible for much of
the damage produced during IR. In fact, aldehyde dehydrogenase 2
(ALDH2) has been reported to protect myocardium against IR in-
jury through detoxiﬁcation of aldehydes [202]. By contrast, low
concentrations of aldehydes can stimulate stress resistance path-
ways to confer cardioprotection. Thus, lipid peroxidation products
are involved in the transcriptional regulation of endogenous an-
tioxidant systems. Recent evidence demonstrates that transient
increases in lipid peroxidation products may be beneﬁcial in car-
dioprotection by contributing to mitohormesis (i.e. induction of
antioxidant systems) in cardiomyocytes. Thus, 4-HNE activates
Nrf2 in the heart and increases the intramyocardial GSH content,
improving the functional recovery of the left ventricle following IR
in isolated perfused hearts [203]. 4-HNE also induces mitochon-
drial uncoupling protein 3 (UCP3) via Nrf2 in cardiomyocytes,
promoting cell survival [204].5. Signal transduction in the context of antioxidant responses:
some key players
Historically considered as cellular damaging agents, ROS have
emerged as important modulators of intracellular transduction
signaling. ROS interact with redox-sensitive signaling molecules
including transcription factors, protein tyrosine phosphatases,
protein kinases and ion channels, that contain cysteine residues
whose SH groups are oxidized, causing a change in their biological
activity, regulating cellular processes like growth factor signaling,
hypoxic signal transduction, autophagy, immune responses, and
stem cell proliferation and differentiation [129,205].
These redox changes include activation/deactivation cycles of
redox metabolism and expression of antioxidant enzymes ex-
pression that are essential to maintain nucleoﬁlic tone and oxi-
dant/antioxidant balance in the cells [130]. In the following section
a brief overview of some examples of redox-sensitive cytosolic and
mitochondrial proteins is given.
5.1. Cytosolic regulation
5.1.1. Protein tyrosine phosphatases
One of the most studied direct targets of ROS signaling is the
family of protein tyrosine phosphatases. All tyrosine phosphatases
have a conserved 230-amino acid domain that contains a reactive
and redox-regulated cysteine, which catalyzes the hydrolysis of
protein phosphotyrosine residues by the formation of a cysteinyl-
phosphate intermediate, that later is hydrolyzed by an activated
water molecule. Because of the unique environment of the tyr-
osine phosphatase active site, the catalytic cysteine presents an
unusually low pKa value and is therefore deprotonated at phy-
siological pH, existing as a thiolate anion (Cys–S). Oxidation of
this residue to sulfenic acid by H2O2 renders the tyrosine phos-
phatases inactive. This oxidation of cysteine to sulfenic acid is
reversible, while oxidation by the addition of two (sulﬁnic acid) or
three (sulfonic acid) oxygens to the active site cysteine is irrever-
sible. These modiﬁcations can be further stabilized by the forma-
tion of inter or intramolecular disulﬁde (S–S) or sulfenyl–amide
bonds. Thus ROS signiﬁcantly inhibit activity of tyrosine phos-
phatases, resulting in increased tyrosine phosphorylation [206].
For instance, redox regulation of protein tyrosine phosphatase 1B
involves a sulfenyl–amide intermediate, also accompanied by large
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binding. This is an unusual protein modiﬁcation that protects the
active-site cysteine residue of PTP1B from irreversible oxidation
[207,208]. Interestingly, S-glutathionylation of the sulfenic acid
form of these proteins is proposed as a mechanism to protect
against irreversible oxidation [209].
5.1.2. Protein Kinases
Protein kinases are a group of enzymes that phosphorylate
tyrosine, threonine, and/or serine residues of target proteins al-
tering their function. Susceptible cysteines in some serine/theo-
nine protein kinases are directly modiﬁed by ROS. Protein kinase C
(PKC) contains a cysteine rich domain susceptible to oxidation,
while oxidation of Cys-245 and Cys-487 in the kinase domain of
the nonreceptor tyrosine kinase Src results in the activation of the
protein [210]. Mitogen-activated protein kinases (MAPKs) are a
family of serine/threonine kinases that play a central role in cou-
pling various extracellular signals to a variety of biological pro-
cesses, such as gene expression, cell proliferation, differentiation,
and cell death. The activity of MAP kinases (ERK, c-Jun and p38) is
regulated by phosphorylation cascades: MAPKs activation is in-
duced through the phosphorylation of their threonyl and tyrosyl
residues within a tripeptide motif TXY by a dual speciﬁcity kinase
termed MAP kinase kinase (MKK), which in turn is phosphorylated
and activated by an upstream kinase called MAPK kinase kinase
(MAPKKK) [211]. However, MAPKs can also be activated by ROS.
In vascular smooth muscle cells, intracellular ROS are critical
for AII-induced activation of p38MAPK, JNK and ERK5, whereas
phosphorylation of ERK1/2 activation in smooth muscle cells is
redox sensitive, in contrast to ﬁbroblasts, suggesting that redox-
regulation of MAP kinases may be ligand- and cell-speciﬁc [212].
Many growth factor and cytokine receptors bearing cysteine-Fig. 7. Induction of antioxidant responses by ROS-mediated activation of cytosolic cell
recruiting c-Fos and c-Jun to the nucleus where they activate the transcription factor AP-
NF-ĸB. Both of these factors are important in regulating diverse genes, including antioxrich motifs can be targets of oxidative stress. Thus, insulin-like
growth factor-I (IGF-I) activates ERK pathway through ROS-medi-
ated activation of EGF receptor, which by mediation of Ras-GTPase
activates Raf and MEK, phosphorylating ERK [213]. ROS may also
activate MAPK pathways through the oxidative modiﬁcation of the
intracellular kinases. ASK-1, a member of the MAP3K superfamily
for JNK and p38, binds to reduced thioredoxin in nonstressed cells.
Upon oxidative stress, thioredoxin becomes oxidized and dis-
sociates from ASK-1, leading to activation of JNK and p38 pathways
through oligomerization of ASK-1 [214].
Another mechanism for MAPK activation by ROS includes the
inactivation and degradation of the MAPK phosphatases (MPKs).
Kamata et al. reported that H2O2 inactivates MKPs by oxidation of
their catalytic cysteine, which leads to sustained activation of the
MAPK pathway [71]. However, Zhou et al. found that upregulation
of MKP-1 expression by H2O2 correlates with inactivation of JNK
and p38 activity [215]. This paradox in the roles of ROS as “in-
ducers” in the regulation of MKP-1 expression and as “inhibitors”
may be, at least in part, related to differences in the concentrations
of ROS and of the redox sensitivity of Cys residues within MAPK
phosphatases.
Some antioxidant responses are also regulated by MAPKs sig-
naling. Activation of mitogen activated protein kinase pathways
induces antioxidant response element-mediated gene expression
via a Nrf2-dependent mechanism [216]. Prx I is an antioxidant that
is up-regulated in a ROS/p38 MAPK-dependent manner [217]. In
addition, MAPK regulates NK-κB activation by modulating the
phosphorylation of IκB-alpha and p65 NF-κB, stimulating iNOS and
AP1 gene expression (Fig. 7) [218]. It also has been reported that
mitogen-activated protein kinases (MAPKs) are involved in some
polyphenol-mediated regulation Phase II enzymes gene expres-
sion and induction of apoptosis [219].signaling pathways. ROS drive activation of MAPKs. ERK and JNK are involved in
1, whereas activation of p38 and IKK is important in the transcriptional activation of
idants (p53, NQO1, GSTs, SOD2, Ap-1,p53, and Prx I).
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Mitochondria are regulated in an intricate manner by oxidants
and electrophiles. The activity of several complexes of the electron
transport chain is modulated by post-translational modiﬁcations
such as S-nitrosylation, S-glutathionylation or electrophile addi-
tions (Fig. 6). As mentioned above, complex I (NADH ubiquinone
oxidoreductase) is modiﬁed by nitric oxide or its derivatives
[177,178,185,220,221] and glutathione [222–225]. The S-ni-
trosylation of complex I correlates with a signiﬁcant loss of activity
that is reversed by thiol reductants. S-nitrosylation was also as-
sociated with increased superoxide production from complex I
[178,185]. The fact that mitochondrial superoxide formation can be
regulated by S-nitrosylation of complex I may play an important
role in mitochondrial redox signalling [226]. Complex I has two
transitional states, the active (A) and the deactive (D) states, and
the complex is S-nitrosylated in the D state [179]. The A to D
transition may take place during hypoxia and this might be im-
portant in the setting of ischemia–reperfusion. Other studies have
reported nitrotyrosine modiﬁcation on the complex [227,228]. In
addition, reversible glutathionylation of complex I increases mi-
tochondrial superoxide production [222]. Other electron transport
complexes, in particular, complex II (succinate dehydrogenase)
and complex V (ATP synthase), have been shown to be modiﬁed by
reactive species [229,230]. Likewise, mitochondrial matrix pro-
teins such as NADPþ-isocitrate dehydrogenase [231,232], α-ke-
toglutarate dehydrogenase [233,234] and aconitase [230,235], as
well as proteins of the intermembrane space such as creatine ki-
nase [236] and cytochrome c [237] can also be modiﬁed by re-
active species, affecting in most cases their catalytic activity.
In response to stress or to an increased demand in energy,
mitochondria produce a limited amount of ROS that act as sig-
naling molecules, initiating a molecular stress response that leads
to transcriptional changes in the nucleus. A transient ROS signal
generates an endogenous response that allows detoxiﬁcation of
ROS by inducing defence enzymes such as superoxide dismutase
or catalase, as well as other stress defence pathways [238]. This
process is called retrograde response [239,240]. The release of ROS
from mitochondria can function in numerous signalling pathways
[241]. Some examples are the regulation of cytosolic stress kinases
[71], modulation of hypoxic signalling [242], and activation of
macroautophagy [243].
In contrast to this function of ROS as signalling molecules,
sustained high levels of ROS can cause intracellular damage. This
nonlinear response to mitochondrial ROS is known as mitochon-
drial hormesis or mitohormesis [240]. This concept considers ROS
as essential signalling molecules, and not just harmful and da-
maging by-products of mitochondrial metabolism.
5.2.1. Targeting mitochondria to eliminate ROS production
Antioxidants can be targeted selectively to mitochondria to
reduce oxidative stress. Mitochondria-targeted antioxidants com-
prise a triphenylphophonium cation (TPPþ) covalently attached to
an antioxidant, which enables mitochondrial delivery of the
compound. The most extensively studied is MitoQ, which contains
the antioxidant ubiquinol covalently attached to TPPþ . MitoQ de-
creases cardiac [244] and renal [245] IR injury and it is therefore a
potential therapeutic agent against this type of damage. Ongoing
clinical trial are evaluating the efﬁcacy of Bendavia, Szeto-Schiller
peptides that also improve post-infarction cardiac function and
post-IR kidney injury post-IR [246–248]. Another strategy to
eliminate harmful ROS generation is the removal of damaged
mitochondria, which can produce excessive ROS. Recent studies
have focused on the inhibition of Drp1 (dynamin-related protein
1), a large GTPase involved in mitochondrial ﬁssion. In particular,
the inhibitor mdivi-1 reduces myocardial infarct size in miceundergoing IR, and reduces excessive fragmentation in adult rat
cardiomyocytes exposed to simulated IR injury [249]. In addition, a
small separation of function peptide, P110, which speciﬁcally af-
fects the interaction between Drp1 and ﬁssion 1, diminishes ex-
cessive mitochondrial ﬁssion and reduces neurotoxicity in cells
derived from patients with Parkinson disease [250]. Another me-
chanism to prevent pathological ROS production consists of
eliminating damaged mitochondria. After cellular insults such as
oxidative stress caused by IR, the elimination of damaged or dys-
functional mitochondria through autophagy (mitophagy) is upre-
gulated by diverse molecular mechanisms [251,252], contributing
to the maintenance of mitochondrial quality control. Finally, other
mechanisms that maintain mitochondrial quality control are the
unfolded protein response and the proteasome machinery, which
are also potential therapeutic targets.6. Conclusion
Since the discovery of ROS there has been increased interest
and research into the processes of ROS generation, ROS-mediated
effects and functional consequences of ROS driven processes. We
now have a relatively comprehensive view of how ROS can be
generated, converted into each other and how their action affects
lipids, proteins and DNA. A concept that has gained momentum in
redox biology and is probably to remain for a long time is the
major importance of hydrogen peroxide as the paradigmatic sig-
naling molecule [253]. However, we still need more knowledge
about how this signaling proceeds, the antioxidant responses in-
volved and their thresholds to redox perturbations. Moreover,
mechanisms of how ROS may be transported or interconverted
inside or outside cellular compartments and how these conver-
sions contribute to cellular homeostasis are lacking. The next few
years may well provide further examples or may uncover new or
alternate mechanisms contributing to redox balance, the anti-
oxidant defense and ROS/peroxide signaling.References
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